NasdaqCM - Nasdaq Real Time Price USD

Soligenix, Inc. (SNGX)

0.4150 -0.0120 (-2.81%)
At close: April 26 at 4:00 PM EDT
0.4150 0.00 (0.00%)
After hours: April 26 at 7:17 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Christopher J. Schaber Ph.D. Chairman of the Board of Directors, CEO & President 625k -- 1966
Dr. Oreola Donini Ph.D. Senior VP & Chief Scientific Officer 342.31k -- 1972
Dr. Richard C. Straube M.D., MSc. Senior VP & Chief Medical Officer 212.2k -- 1952

Soligenix, Inc.

29 Emmons Drive
Suite B-10
Princeton, NJ 08540
United States
(609) 538-8200 https://www.soligenix.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
13

Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Corporate Governance

Soligenix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
Soligenix, Inc. Earnings Call

Related Tickers

PXMD PaxMedica, Inc.
0.7398
+5.06%
 
NKGN NKGen Biotech, Inc.
1.6100
-18.69%
 
ADIL Adial Pharmaceuticals, Inc.
1.6100
-6.94%
 
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
 
BPTH Bio-Path Holdings, Inc.
2.6800
+1.71%
 
LGVN Longeveron Inc.
1.7500
+4.79%
 
ALLR Allarity Therapeutics, Inc.
1.4600
+2.10%
 
PHIO Phio Pharmaceuticals Corp.
0.6820
+1.34%
 
PCSA Processa Pharmaceuticals, Inc.
2.1500
-11.52%
 
TCBP TC Biopharm (Holdings) Plc
1.5300
-2.55%